Just to add a note about the perceived competition and Immutep's...

Just to add a note about the perceived competition and Immutep's pipeline.
Efti has no competition. Its an Immune booster or down regulator (761).

Eftilagimod alpha binds to a subset of MHC class II molecules to control antigen-presenting cell activation as well as CD8 T-cell activation. This mechanism of action may lead to stronger anti-tumor responses.

Efti has the potential to work in combo with almost any other oncology drug. Low cost, easy application, durable responses.

However. Efti is a 'pipeline in a product' which is the only platform Immutep have (excluding 761 - which remains pre-clinical).

Other immuno-oncology biotechs attack cancer in many different ways but the phrase that resonates with me is 'curative intent'.
Therefore curing cancer is now on the radar, not improving OS by months, but cancer obliteration.

I believe looking forward within 5 years, cancer patients will be first tested and analysed for mutation type(s) and prescribed 'precision medicines', which could (will) include Efti and a concoction of drugs checkpoints/viruses etc to kill the specific cancer(s). Forever.

Maybe a pipe dream? But like many who invest in oncology, I have seen first hand the devastation that cancer causes.......